A recent phase III clinical trial (BEVERLY) investigating the combination of bevacizumab with erlotinib for the treatment of advanced EGFR-mutated NSCLC recruited study patients mainly in European countries (45). Here, EGFR is linked to non-small cell lung carcinoma.